INTRODUCTION
Treat to target guidelines for patients with rheumatoid arthritis (RA) recommend to tailor treatment to achieve a state of remission, or at least low disease activity. [1] [2] [3] The merits of achieving these low disease activity targets might seem self-evident to rheumatologists but may be less clear to other stakeholders. As many as half of RA patients starting a biologic fail to attain a state of remission or low disease activity, despite experiencing some clinical improvement (e.g. an ACR50 response, or clinically relevant improvement in the Disease Activity Score). 4 However, some evidence suggests that for such individuals, patient-reported outcomes may be improved even further if remission or low disease activity can be attained. 5 The benefits of lower disease activity states on other important outcomes including serious adverse events (e.g., hospitalizations) and emergent healthcare services (e.g., visits to the emergency department [ED] ) are uncertain. Conversely, it is possible that tighter control of disease activity may have unintended consequences if more intensive management is required, including treatment with multiple immunosuppressive medications, which could put patients at greater risk for side effects. Given that more intensive strategies often entail use of expensive RA therapies, the economic impact of more aggressive RA treatments to achieve more intensive disease activity targets is not clear. Finally, it may be difficult for patients to accept acceleration of treatment given concerns regarding perceived risk of toxicity. Physicians need to be able to deconstruct these fears with tangible examples of the benefits of lower disease activity in terms that will be meaningful for patients.
As a first step to understand whether remission or low disease activity might have an impact on safety outcomes and associated costs, we evaluated clinical and economic outcomes associated with lower disease activity states using data from the U.S. Corrona RA registry, with a linkage to administrative data for outcome ascertainment. We hypothesized that lower disease activity would be associated with fewer ED visits, a lower likelihood of all-cause hospitalization, a lower risk for all-cause mortality, and lower healthcare costs. Our analysis also serves as an example of a linkage between an outpatient disease registry and administrative claims to address a scientific question for which both types of data would be required.
METHODS

Data source and eligible patient population
The Corrona registry is an independent, prospective observational cohort of patients with RA. Patients are recruited from more than 165 private and academic practice sites across 40 states in the United States, with 625 participating rheumatologists, with median patient follow-up of 2.9 years.
Corrona registry patients were eligible if they had rheumatologist-confirmed RA and contributed at least two visits to the registry. Corrona data were linked to administrative data from the U.S. Medicare system (n = 4876) using methods previously described. 6 Patients were allowed to enter into follow-up on the date when they met both of the following criteria: (i) date of their second Corrona visit and (ii) the date of 6 months of full observability/coverage (Medicare part A [inpatient] and B [outpatient], and not having part C [Medicare Advantage]) coverage (n = 4750). These requirements ensured a complete history available in both the registry and linked Medicare medical data. The final analysis population included those who had full information in the registry necessary to characterize their RA and associated comorbidities (n = 4593), as described next. All patients provide consent to participate in the registry, and the Medicare data was governed by a data use agreement from the Center for Medicare and Medicaid Services.
Rheumatoid arthritis disease activity
Using registry data, the main independent variable of interest was disease activity, which was measured by the Clinical Disease Activity Index (CDAI), 7 a commonly used metric that does not require a lab to be available in real time. If one of four components of CDAI was missing, that same component of the previous visit's CDAI was carried forward, conditional on it not being missing. The area under the curve (AUC) of the CDAI was calculated at the start of follow-up and updated at the time of each registry visit, computed using the trapezoidal rule that calculated the mean CDAI between each pair of registry visits, and weighted by the amount of time between visits. This measure is described hereafter as the cumulative time-weighted average CDAI. For visit intervals that extended beyond 6 months, the CDAI was imputed using the geometric mean between the prior visit and the next visit. In the main analysis, CDAI was modeled using this method, and in a sensitivity analysis, the CDAI from only the most recent registry visit was used as the main exposure variable. Additional analyses substituted each of the 4 CDAI components for the composite CDAI to compare the strength of association between them for each of the four outcomes.
Clinical and economic outcomes
The three clinical outcomes of interest included inpatient hospitalization, a composite of inpatient hospitalization or ED visit, and all-cause mortality. Medicare data include healthcare encounter billed for by the healthcare system, and also capture vital status and date of death but not cause of death. As a fourth outcome of interest, healthcare costs were computed using the allowed amounts actually reimbursed to healthcare systems by the Center for Medicare and Medicaid Services, excluding the cost of parenterally administered biologics for RA that billed under part B. A subgroup analysis restricted the cohort to individuals who had part D for the entirety of their follow-up time. In this subgroup of patients, we re-examined the cost outcome and included not only medical costs but also the costs of parenterally administered biologic drugs (from Medicare part B) as well as part D outpatient drug costs. Costs were calculated as 2016 Medicare-paid amounts and were adjusted for inflation based on the Medical Care component of the Consumer Price Index.
Comorbidity
Patients with a higher burden of comorbidities might have a differential likelihood to reach lower disease activity states, and the observed disease activity and outcome associations might differ in sicker people and yield confounding of our main exposure-outcome associations. Therefore, we classified patients into distinct comorbidity groups using both registry and Medicare data. Information from the registry included number of past Disease Modifying Anti-Rheumatic Drug (DMARDs) including biologics, the number of non-biologic DMARDs, the Modified Health Assessment Questionnaire (mHAQ), (a measure of functional status), steroid dose group (none, <7.5 mg/day, ≥7.5 mg/day), and physician-assessed RA disease severity on a 1-4 ordinal scale. Comorbidities and healthcare utilization from the Medicare data included the Charlson comorbidity score, 8, 9 the sum of the 34 Elixhauser comorbidity index conditions, 10 the number of physician visits, the number of hospitalizations, the number of unique medication classes as defined by the American Society of Health System Pharmacist classification, disability as formally assigned by Medicare as the original reason for entitlement, the sum of the 254 Agency for Healthcare Research and Quality (AHRQ) Clinical Classification Software conditions, an adapted comorbidity score applicable to rheumatic disease patients, the Rheumatic Disease Comorbidity Index, 11 and total healthcare costs paid by Medicare. All registry-derived covariates were assessed at the visit at which follow-up began (baseline), and in the Medicare data, in the 6 months prior to baseline.
Because the methods described previously that assess the severity of illness were anticipated to have appreciable collinearity and shared variance, we reduced the dimensionality of these conditions through principal components analysis. 12 This method reduced the variance shared between the 14 illness measures and created a series of orthogonal principal components vectors. The proportion of variance explained was described according to the number of principal components. K-means clustering was then applied to the principal components vectors to identify comparable patient phenotypes grouped on the basis of the severity of their comorbidities, with a goal of deriving four clusters. For the clustering procedure, 20 random starts were used so as to avoid finding a non-robust local optimum, and the best selected based upon minimization of the mean squared error. The clusters were then plotted three dimensionally on the axes of the first three principal components vectors.
Statistical analysis
The eligible patient cohort was characterized descriptively by comorbidity patient phenotype. The extent of missingness in key variables was low (CDAI 2.3% of visits; glucocorticoid dose 1.7%, comorbidity phenotype 3.0%), and complete case analysis was used without imputation. The incidence rates (IRs) of ED visits, hospitalization, and death then were calculated for each category of RA disease activity, remission, low, moderate, and high using published CDAI cutpoints. 7 Ninety-five percent confidence intervals for the IRs were calculated using a Poisson distribution. 13 We also enumerated the top ten primary diagnosis codes associated with inpatient hospitalizations, the composite of hospitalization and ED visits (not resulting in hospitalization), and as a proxy for cause of death for the mortality outcome, the subgroup of hospitalizations where the patient died during the hospitalization or in the next 30 days. Date of death but not cause of death was available in this data, so these diagnoses were used as proxies for cause of death. This approach is consistent with past epidemiologic studies that define "fatal myocardial infarction" or "fatal stroke" as myocardial infarction or stroke events that are followed by death within 28-30 days.
14 Cox proportional hazards modeling was used to estimate each of the outcomes of interest, updating the cumulative, time-weighted average CDAI at each Corrona visit, and using it as the predictor variable for the ensuing visit interval. In each of the three separate event analyses (one per outcome), follow-up time was censored at the time of the first event. Censoring also was applied if there was a gap of more than 12 months between Corrona visits, more than one missing CDAI component, death or other reason for termination in the registry, or the end of follow-up in Medicare (loss of Medicare A + B À C + D coverage, or 31/12/2012). In the sensitivity analysis, censoring was not applied if CDAI was missing, but rather, the person-time associated with missing CDAI was excluded until a non-missing CDAI was available from the registry. In all models, moderate disease activity was referent given that a large fraction of RA patients remain in moderate disease activity despite the availability of effective RA therapies. 4 This analysis was intended to inform the potential benefits of better disease activity states, including both low disease activity and remission. The cost data were analyzed with mixed models using a Gaussian distribution with a log transformation. Based on factors hypothesized to be potential confounders between RA disease activity and the outcomes of interest, each model adjusted for comorbidity cluster membership, age, sex, RA disease duration, RA seropositivity, and glucocorticoid use. Model discrimination was assessed using the c index, 15, 16 similar to the c statistic in a logistic regression model. 17, 18 All analyses were conducted using SAS 9.4.
RESULTS
Among the 4750 RA patients potentially eligible for analysis, 4593 were included. The majority of the drop in sample size was due to missingness in current steroid dose (n = 78), mHAQ (n = 47), and physicianassessed severity of RA (n = 20) assessed at the start of follow-up in the registry. Seven of the principal components vectors in the PCA explained more than 80% of the variance in the assessments of comorbidity and illness severity. Using k-means clustering, there were four distinct clusters of patients formed with good discrimination, as shown in Figure 1 . The corresponding patient characteristics are described in Table 2 . In the analysis using time-weighted cumulative CDAI (Table 2 , top half), there were 1819 hospitalizations, 2499 hospitalization or ED visits, and 313 deaths. Patients in remission had the lowest rate of all three types of events, and a strong dose-response relationship between disease activity category and event IR was observed. The same trends were observed in annual costs. Patients in remission had the lowest annual medical costs ($11 145), and those in high disease activity had the highest costs ($20 449), a crude difference of $9304. The difference between remission and moderate disease activity was $6500/year. Results were very similar when the most recent visit's CDAI was used ( Table 2 , bottom half). The IR of hospitalization stratified by comorbidity cluster membership is shown in Figure 2 . A dose-response relationship was observed, with higher rates of hospitalization occurring as disease activity increased, and as the comorbidity cluster group ranged from the least ill patients to the most ill patients. Patients within each cluster contributed to all four disease activity groups. However, patients in the least ill comorbidity group (Cluster 1) contributed 87% of their exposure time to the remission or the low disease activity categories, whereas patients in the other three cluster categories contributed 57-78% of their exposure time to the remission or low disease activity categories.
The top 10 diagnoses associated with the inpatient and ED visits and hospital-associated mortality are shown in Table 3 . Hospitalizations and ED visits for osteoarthritis/joint replacement, infections, and cardiovascular conditions were the most common categories of events. Of the 313 deaths, 206 (66%) occurred within 30 day of hospital admission. The most common primary hospitalization diagnoses associated with these fatalities were septicemia, respiratory failure, pneumonia, and stroke events. Table 4 describes the multivariable-adjusted association between RA disease activity and various outcomes. As shown, and after adjustment for potentially confounding factors including comorbidity cluster membership, patients in remission and low disease activity consistently had significantly lower event rates for each event type compared with patients in moderate disease activity. Remission was associated with a 32% lower rate of all cause hospitalization, a 24% lower rate of ED visits or hospitalization, and a 37% lower rate of mortality. For the hospitalization model, the c index of a model with age alone was 0.55 and increased to 0.62 after adding the comorbidity clusters, and to 0.64 with the CDAI, and improved negligibly after including all remaining covariates. In the separate cost model, remission was associated with $3133/year lower healthcare costs compared with patients in moderate disease activity. Of the four components of the CDAI, the patient global was the statistically strongest predictor in all models in Table 4 ; it was significant when substituted for the CDAI, and remained significant when the other three CDAI components were also included (not shown).
The magnitude of benefit associated with low disease activity (compared with moderate) was smaller and associated with a 13% low rate of hospitalization and 13% ED/hospitalizations, and a 15% lower rate of mortality, and $1629 lower annual costs. Glucocorticoid dose consistently was associated with higher rates of all outcomes and higher costs (Table 4 ). There was no interaction between CDAI category and cluster membership (p > 0.20 for each interaction term). The adjusted results from the sensitivity analysis that used only the most recent CDAI were similar (Appendix Table 1 ).
The subgroup analysis of RA patients who had part D medication coverage over their entire follow-up (n = 1445 patients) estimated both medical costs and medication costs, for both parenteral drugs (e.g., infused biologics) and outpatient medications. Over the entire follow-up period, the distribution of biologic-exposed person time varied by disease activity category and was 40% (remission), 45% (low disease activity), 51% (moderate), and 52% (high disease activity). Patients in remission incurred annual costs of $25 148, which after adjustment, was $4718 per year less than patients in moderate disease activity (Appendix Table 2 ).
DISCUSSION
In this analysis of older RA patients participating in a large U.S. registry with a linkage to Medicare administrative data, we observed significantly lower rates of hospitalizations, ED visits, mortality, and medical costs associated with remission. Those in low rather than moderate disease activity likewise had lower associated rates of hospitalization and mortality, although the magnitude of the difference was smaller.
As expected, those in high disease activity states had the highest rates of all outcomes and the greatest healthcare costs. Given that many patients initiating biologics improve but reach only moderate disease activity rather than low or remission disease states, our findings provide additional support for the treat to target goals recommended by international and U.S. guidelines.
1,2
Our results are consistent with prior literature showing lower risks for specific medical events associated with better (lower) disease activity states. A study by Crowson et al. studied 525 RA patients and found lower rates of cardiovascular disease associated with patients in remission and among those who did not have a recent RA flare. 19 Prior results from the Corrona registry that included not only older but also younger RA patients found a lower rate of myocardial infarction, stroke, and CHD death for those in lower disease activity states. 20 Additionally, results from the British Society of Biologic Registry found that patients receiving anti-TNF therapy had a lower risk of myocardial infarction, but only if they achieved lower disease activity. 21 Our grouping of comorbidities using principal components analysis and k-means clustering yielded distinct groups of RA patients with different phenotypes and took advantage of the availability of comorbidity information from both registry and claims data sources. Cluster 1 included RA patients who were relatively healthy with a low prevalence of comorbidities, similar to most other RA disease cohorts. 22 Cluster 2 might be characterized as younger, largely disabled patients with longstanding RA and represents a unique group of RA patients, many of whom qualify for Medicare eligibility on the basis of disability rather than age. Clusters 3 and 4 were older RA patients with high comorbidity burdens. While cluster membership was strongly associated with each of the outcomes, even for patients in remission, there was no statistical evidence for effect modification by cluster.
The medical costs associated with being in a lower disease activity state deserve mention. The incremental cost savings associated with being in remission ($11 145) compared with moderate disease activity ($17 646) was $6501/year (crude) and $3133 (adjusted). In purely economic terms, if a patient required a biologic to move from moderate disease activity to remission, the lower medical costs associated with being in remission would not be offset by the high cost of biologic therapy, typically >$30 000/year. While the forthcoming availability of biosimilar medications is likely to substantially reduce biologic costs, they still are unlikely to make continued used of a biologic cost-saving for a health plan. However, although biologics may not be cost saving in the short term, the incremental potential benefits on patient's nearterm quality of life, work productivity, downstream reduction of progression of underlying comorbidities, Note: n's refer to the number of outcome events, ignoring small variations in exposure time related to how disease activity was characterized, as described in the Methods section. ED = emergency department; MI = myocardial infarction; COPD = chronic obstructive lung disease; RA = rheumatoid arthritis. *where death occurred in the hospital or within 30 days (n = 206, 66% of all 315 deaths) reduction in future joint damage and disability, etc. are additional benefits that were not explicitly represented in this analysis. The strengths of our study include the ability to examine outcomes using a relatively novel integrated data source that linked administrative claims to a large U.S. outpatient disease registry to conduct an analysis that neither data source alone could accommodate. Additionally, our focus on older patients and relatively large sample size yielded adequate power to study serious adverse event-related differences between disease activity states. We controlled for multiple comorbidity indices derived both from registry and administrative data sources. The methods implemented to characterize discrete patient phenotypes based upon their comorbidity burden appeared useful and might be a desirable framework to consider for future studies, particularly when multiple types of data are available, such as a registry linked with health plan data.
Several design features of our study should be considered in interpreting our results. First, we used registry data linked to administrative data from Medicare, a program that typically enrolls older patients (age ≥ 65) or those with disabilities, including RA. As such, these results may not be generalizable to younger RA patients. We also recognize that the deterministic methods used to link to the administrative data did not link all RA patients in Corrona with Medicare, although prior work has shown only small differences between linked and not linked patients. 6 Additionally, as in all observational analyses, results may be subject to misclassification and residual or unmeasured confounding. This is particularly relevant in being able to adequately adjust for comorbidities, which despite being ascertained both from the registry and administrative claims data, are presumably imperfectly measured in both. We also recognize that while we did not find a significant interaction between CDAI and the comorbidity phenotype, this analysis may have been underpowered to detect this effect modification. Finally, despite our attempts to use reasonable methods to control for multimorbidity, we cannot rule out the possibilities of residual confounding, informative censoring or reverse causation (i.e., that we are observing the effect of multimorbidity on adverse events and costs).
In conclusion, we found that better RA disease activity states were associated with lower rates of hospitalizations, ED visits, mortality, and medical costs. While results from this observational study should be interpreted cautiously and causal relationships not inferred, these findings do provide information regarding safety benefits potentially able to be achieved for patients who achieve lower disease activity states, along with associated savings in healthcare costs.
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KEY POINTS
• Many patients with rheumatoid arthritis have improvement in their condition after treatment, yet remain in a state of moderate disease activity. The potential incremental benefit on safety events and healthcare costs associated with attaining low disease activity or remission compared to moderate disease activity is unclear.
• We linked a large U.S. registry to health plan data to leverage the richness of both data sources to characterize disease activity and comorbidities. Outcomes included all-cause hospitalizations, emergency department visits, mortality, and medical costs.
• Low disease activity and remission was associated with incrementally reduced risks of hospitalization, ED visits/hospitalization, death, and lower medical costs. These results suggest benefit of treating patients aggressively to reduce serious adverse events and minimize healthcare costs.
